Pigment Epithelium-Derived Factor Blocks Tumor Extravasation by Suppressing Amoeboid Morphology and Mesenchymal Proteolysis  by Ladhani, Omar et al.
Pigment Epithelium–Derived
Factor Blocks Tumor
Extravasation by Suppressing
Amoeboid Morphology and
Mesenchymal Proteolysis1,2
Omar Ladhani*,†, Cristina Sánchez-Martinez*,†,‡,3,
Jose L. Orgaz§,¶, Benilde Jimenez§
and Olga V. Volpert*,†
*Department of Urology, Northwestern University Feinberg
School of Medicine, Chicago, IL, USA; †Robert H. Lurie
Comprehensive Cancer Center, Northwestern University,
Chicago, IL, USA; ‡Fundación Inbiomed, San Sebastián,
Guipuzcoa, Spain; §Department of Biochemistry,
Universidad Autónoma de Madrid (UAM) and Instituto
de Investigaciones Biomédicas Alberto Sols CSIC-UAM,
Madrid, Spain; ¶Randall Division of Cell & Molecular
Biophysics, King’s College London, London, UK
Abstract
Metastatic melanoma cells are highly adaptable to their in vivo microenvironment and can switch between protease-
dependentmesenchymal and protease-independent amoeboid invasion to facilitate metastasis. Such adaptability can
be visualized in vitro, when cells are cultured in conditions that recapitulate three-dimensional microenvironments.
Using thick collagen layers in cell culture and in vivo extravasation assays, we found that pigment epithelium–derived
factor (PEDF) suppressed lung extravasation of aggressive melanoma by coordinated regulation of cell shape and
proteolysis. In cells grown on a thick collagen bed, PEDF overexpression and exogenous PEDF blocked the rapidly
invasive, rounded morphology, and promoted an elongated, mesenchymal-like phenotype associated with reduced
invasion. These changes in cell shape depended on decreased RhoA and increased Rac1 activation and were medi-
ated by the up-regulation of Rac1-GEF, DOCK3 and down-regulation of Rac1-GAP, ARHGAP22. Surprisingly, we found
that PEDF overexpression also blocked the trafficking of membrane-tethered, MT1-MMP to the cell surface through
RhoA inhibition and Rac1 activation. In vivo, knockdown of Rac1 and DOCK3 or overexpression of MT1-MMP was
sufficient to reverse the inhibitory effect of PEDF on extravasation. Using functional studies, we demonstrated that
PEDF suppressed the rounded morphology and MT1-MMP surface localization through its antiangiongenic,
34-mer epitope and the recently identified PEDF receptor candidate, PNPLA2. Our findings unveil the coordinated
regulation of cell shape and proteolysis and identify an unknown mechanism for PEDF’s antimetastatic activity.
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Introduction
During malignant progression, melanocytes acquire proinvasive char-
acteristics that enable metastasis, the primary cause of cancer-associated
death. Metastasis involves multiple events including detachment from
the primary site, intravasation and survival in circulation, extravasation,
and implantation at distant sites followed by proliferation [1].Melanoma
is a highly aggressive, undifferentiated lesion that rapidly acquires single-
cell migration strategies allowing tissue invasion and colonization [2].
Moreover, depending on the microenvironment, it can switch from a
slow, mesenchymal-like manner to a rapid, amoeboid mode of invasion
[3]. The mesenchymal-like melanoma cells are characterized by elon-
gated spindle shape and by actin-rich filopodia and lamellipodia at
the leading edge [4]. Such cells are forming contacts with the extra-
cellular matrix (ECM) and their motility requires integrin signaling,
matrix metalloproteinases (MMPs), especially membrane type 1 matrix
metalloprotease (MT1-MMP), and Rac1 function [4,5]. Integrins clus-
ter at the focal adhesions and subsequently recruit MT1-MMP, which
digests ECM and recruits and activates secreted MMP-2 and MMP-13
[6]. Amoeboid-like cancer cells appear rounded and rapidly change
shape while migrating. They exhibit minimal protease activity; instead,
they form bleb-like protrusions and move through existing spaces
within the ECM. Their rapid deformability is dependent on RhoA
and its downstream target Rho/ROCK kinase (ROCK), which phos-
phorylates myosin II light chain (MLC) and increases actomyosin con-
tractility [7]. Extreme adaptability of the melanoma cells to diverse
microenvironments depends on the switch from the mesenchymal-like
to amoeboid morphology (mesenchymal-to-amoeboid transition,
MAT) and back (amoeboid-to-mesenchymal transition, AMT) [8].
Such adaptability may explain poor efficacy of the broad-spectrum
MMP inhibitors in clinical trials [9].
Pigment epithelium–derived factor (PEDF) is a ubiquitously ex-
pressed secreted protein that suppresses tumor growth and metastasis
by targeting tumor cells and their microenvironment. In the micro-
environment, PEDF induces apoptosis of the endothelial cells [10,11]
through nuclear factor κB (NF-κB) and its downstream target Fas
ligand (CD95L). Conversely, PEDF decreases endothelial cell survival
by blocking the nuclear factor of activated T cells and, consequently,
prosurvival FLICE-inhibitory protein (c-FLIP) [12,13]. We recently
demonstrated that PEDF expression is high in melanocytes and poorly
aggressive melanoma and is lost during the transition to a highly ag-
gressive, metastatic state [14]. Our group and others showed that
PEDF inhibits melanoma migration and invasion and significantly
reduces metastasis [14,15], but the underlying molecular events re-
mained unknown.
MT1-MMP is required for mesenchymal stem cell migration and
invasion and is also critical for tumor invasion [16,17]. MT1-MMP
is processed and activated in the trans-Golgi network before arrival at
the plasma membrane [18,19]. Once tethered to the plasma mem-
brane, MT1-MMP facilitates the activation and secretion of MMP-2
and MMP-13 and promotes local invasion in three-dimensional
ECM environments [20–22]. MT1-MMP is enriched at the invado-
podia, actin-based membrane protrusions typical of invading tumor
cells [23], where it associates with β1-integrin clusters that interact
with the ECM along the leading edge of the cell and facilitates trac-
tion and matrix degradation [4,6].
Few studies examine the connection between the regulation of
tumor cell morphology and MT1-MMP activity. Here we show that
PEDF, a potent antiangiogenic and antimetastatic protein, which is lost
in highly aggressive, metastatic melanoma [14], suppressed extra-
vasation and colonization of the lung parenchyma, in vivo, and link
PEDF’s antimetastatic action with a novel molecular function; PEDF
inhibited the amoeboid and stimulated a mesenchymal-like morphol-
ogy by blocking RhoA and inducing Rac1 activity, thus shifting the
balance in favor of Rac1. Conversely, PEDF attenuated MT1-MMP
function by preventing its distribution to the plasma membrane. Un-
expectedly, PEDF-dependent blockade of MT1-MMP transport to cell
surface was also mediated by the shift in RhoA/Rac1 balance. We con-
clude that PEDF’s antimetastatic action has two distinct facets: the re-
pression of amoeboid invasion and the restriction of proteolytic activity
in mesenchymal-like melanoma cells. We also mapped PEDF’s anti-
metastatic effects on melanoma to its antiangiogenic, 34-mer peptide,
and demonstrated the involvement of the candidate receptor, PNPLA2
(PEDF-R).
Materials and Methods
Cells
Human melanoma cell lines C81-61 and C8161 were from Dr
Hendrix (Children’s Memorial Hospital, Chicago, IL). SBcl2 line
was provided by Dr Herlyn (Wistar Institute, Philadelphia, PA)
and A375 was from ATCC (Manassas, VA). All cells were maintained
as frozen stocks. After transfections or viral infections, only pooled
clones were used to avoid clonal variations. The cells were cultured
as previously described [24–26]. Human primary melanocytes and
the medium were from Cascade Biologic (Invitrogen, Carlsbad, CA).
Expression and Silencing Vectors
For inducible expression, full-length PEDF was cloned into a mul-
tiple cloning site of the lentiviral vector, pLVX-Proteotuner (Clontech,
Mountain View, CA), in-frame with the destabilization domain. The
addition of (250 nM) Shield1 to the culture medium protects PEDF
from proteasomal degradation causing rapid accumulation. PEDF and
its functional epitopes, 34-mer and 44-mer, were cloned previously
[27]; we subcloned them in a lentiviral vector, prrl.CMV.EGFP.wpre.
SIN [14]. Primer sequences are given in Supplementary Methods.
MT1-MMP cloned into a pcDNA3.1 (+) backbone was a gift from
Dr Steve Weiss (University of Michigan, Ann Arbor, MI).
All knockdowns were performed using the human lentiviral
shRNAmir vector, GIPz (Open Biosystems, Huntsville, AL). For
each target, we tested at least two short hairpin RNA (shRNA) con-
structs and chose the most efficient one (Supplementary Methods).
All targets were silenced by more than 70% as was verified by quan-
titative reverse transcription–polymerase chain reaction (qRT-PCR;
Figure W1). A nonsilencing (NS) sequence unable to target mamma-
lian genes was used as a negative control. For shRNA sequences and
testing, see Supplementary Methods.
Lentivirus Production, Transduction, and
Plasmid Transfection
Lentiviruses were generated by cotransfecton of HEK-293T cells
with lenti-X HT packaging system (Clontech) and the viral vector
constructs. Culture supernatants were collected, concentrated, titrated,
and used for viral transduction as described previously [14]. Infected
cells were identified by GFP expression, enriched by cell sorting, and
maintained in puromycin. Plasmid transfections were performed using
Effectene reagent (Qiagen, Valencia, CA).
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Western Blot Analysis and Antibodies
Western blot analysis was performed using a standard method
with polyvinylidene fluoride membranes and the following anti-
bodies: PEDF (BioProducts MD LLC, Middle Town, MD), RhoA
and Cdc42 (Cell Signaling, Danvers, MA), Rac1 (Millipore, Billerica,
MA), DOCK3 (AbCam, Cambridge, MA), p-MLC (Cell Signaling),
MMP-2 (Cell Signaling), and MT1-MMP (Sigma-Aldrich, St Louis,
MO). All Western blot analyses were performed three times with the
exception of Rac1 pull-downs when DOCK3 and/or ARHGAP22
were silenced; in this case, pull-downs were performed as a functional
control to verify knockdown (in addition to qRT-PCR). ImageJ soft-
ware (National Institutes of Health, Bethesda, MD) was used to
quantify Western blots.
RNA Extraction and qRT-PCR
Total messenger RNA (mRNA) was extracted with Qiagen RNeasy
kit (Qiagen) and reverse-transcribed using SuperScript cDNA synthesis
system (Promega, Madison,WI). Quantitative RT-PCR was performed
with Perfecta SYBR Green SuperMix (Quanta Biosciences, Gaithersburg,
MD) in Chromo4 thermal cycler (MJ Research, Waltham, MA; see
Supplementary Methods for primer sequences). Each sample was tested
in triplicate, and each experiment was repeated at least three times.
Ribosomal Protein L19 was used as a reference mRNA in all qRT-
PCR experiments. Representative experiments are shown.
Amoeboid/Mesenchymal Morphology Assays
Amoeboid/mesenchymal morphology assays were performed as
previously described [28]. Twelve-well plates were coated with 700 μl
of 1.7 mg/ml bovine type 1 collagen (GIBCO, Carlsbad, CA) in serum-
free medium and incubated at 37°C for 1 hour. Twenty-five thousand
cells were seeded in full medium atop the collagen layer. After 24 hours,
the medium was replaced with low-serum (1%) or serum-free medium
(SBcl2), and the cells were incubated an additional 16 hours. In the case
of exogenous PEDF, the cells were incubated in low-serum medium
(with PEDF) for 36 to 40 hours. Digital images of ten random fields
(>500 cells treatment) were used to score the percent of elongated cells
per field. Cells were classified as elongated when the length of longest
process exceeded the length of the cell body by a factor of 2 or more.
Statistical Analysis
Statistical significance was determined using one-tailed Student’s t test.
All quantitative assays were performed in triplicate and reproduced
three or more times.
Rho GTPase Pull-down Assays
Cells were serum-starved overnight in medium supplemented
with 0.1% BSA and subsequently stimulated with EGF (100 ng/ml;
PeproTech, Rocky Hill, NJ). Cell lysates were incubated 90 minutes
on a rotating shaker at 4°C with either Rhotekin-RBD or PAK-GST
beads (Cytoskeleton, Denver, CO) to detect active RhoA and Rac1/
CdC42, respectively. The beads were washed in 50 mM Tris-HCl
(pH 7.5) containing 1% Triton X-100, 150 mM NaCl, 10 mM
MgCl2, protease inhibitor, and eluted with 2× sample buffer. An
aliquot of total cell lysate was removed before pull-down to assess total
Rho GTPase levels. Proteins were separated on 4% to 20% gradient
polyacrylamide gels and transferred to polyvinylidene fluoride mem-
branes, which were probed for RhoA, Rac1, or Cdc42, respectively.
Experimental Animals
Immunodeficient mice (Nu/Nu; Harlan, Indianapolis, IN) were
maintained and handled at Northwestern University Center for Com-
parative Medicine according to the National Institutes of Health guide-
lines and treated according to the protocol approved by Northwestern
University Animal Care and use Committee.
Lung Extravasation Assay
Lung extravasation assays were performed as previously described [29],
with modifications. A375 melanoma cells were transduced with prrl.
CMV.EGFP.wpre.SIN bicistronic lentiviral vector, control/empty
(LV-C), or encoding PEDF (LV-PEDF) in combination with pGIPz
LV-shRNAmir encoding shRNA-NS, DOCK3, or Rac1. All lentiviral
vectors encoded GFP to facilitate imaging. The cells were injected
into the tail vein of immunodeficient mice (Nu/Nu; Harlan). Three
to five mice were used for each data point. The mice were killed 2
and 22 hours after injection, and the lungs were analyzed for GFP-
positive tumor cells using Nikon AZ-100 epifluorescence macroscope
(Nikon Instruments, Melville, NY) with a 5× objective.
Immunofluorescence
Cells grown on glass coverslips were fixed with 4% paraformalde-
hyde and permeabilized in 0.1% Triton X-100. Samples were blocked
in 10% normal donkey serum, incubated overnight at 4°C with vin-
culin (AbCam) or MT1-MMP antibody (Sigma-Aldrich) and visual-
ized with fluorophore-conjugated secondary antibody (Jackson
Immunoresearch, West Grove, PA). Nuclei were counterstained with
4,6-diamidino-2-phenylindole, and the slides were mounted in
Flouromount-G (Southern Biotech, Birmingham, AL). F-actin was
visualized using conjugated phalloidin (Molecular Probes Invitrogen).
Digital images were obtained using inverted epifluorescence micro-
scope Eclipse TE200 (Nikon, Melville, NY).
Gelatin Zymography
The cells were starved overnight with 0.1% BSA, treated with 10 nM
PEDF (where indicated), and conditioned medium was collected. In
some experiments, MMPs were concentrated by incubation with gelatin-
coated agarose beads (Sigma-Aldrich) at 4°C for 90 minutes. Sam-
ples were run on criterion zymogram gels containing gelatin substrate
(Bio-Rad, Hercules, CA), renatured in 2.5% Triton, and developed at
37°C overnight. Gels were then fixed and stained with Coomassie
Brilliant Blue. Activity was quantified using ImageJ software.
Results
PEDF Suppresses Amoeboid Morphology
We previously showed that PEDF inhibited human melanoma
metastasis in mice [13,14]. Because the amoeboid morphology is often
associated with rapid invasion and increasingly metastatic behavior in
melanoma [5], we sought to determine how PEDF affects melanoma
morphology. In vitro, we used an inducible lentiviral expression system
that allows rapid PEDF expression (iPEDF). Briefly, PEDF was tagged
with proteasome-targeting degradation domain, which is masked by
a small-molecule inhibitor, shield1. On addition of shield1, PEDF
was stabilized and accumulated at high levels within 30 minutes
(Figure W2A). We transduced A375 melanoma, a cell line that expresses
no detectable PEDF, with iPEDF or control vector and evaluated cell
morphology in the presence and in the absence of shield1.Within 3 hours
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of shield1 addition, PEDF-expressing cells assumed an elongated shape
and protrusions consistent with mesenchymal-like morphology
(Figure 1A). In agreement, we observed that PEDF knockdown in
primary human melanocytes, which express high endogenous PEDF
levels, reduced the number of processes (Figure W3). Furthermore,
iPEDF expression in A375 melanoma decreased the levels of phos-
phorylated myosin light chain, a marker of actomyosin contractility
and amoeboid phenotype (Figure 1B).
We therefore tested if PEDF could suppress the amoeboid pheno-
type of cells grown on a thick collagen layer, representative of a three-
dimensional matrix. Constitutive PEDF overexpression in A375 using
lentiviral vector (Figure W2, B and C ; LV-PEDF) or treatment with
exogenous recombinant PEDF (rPEDF; Figure W4) significantly in-
creased the percentage of elongated cells compared with the vector con-
trol (LV-C) (Figure 1C ). In agreement, PEDF knockdown in poorly
aggressive cell line, SBcl2, which expresses high PEDF and possesses
a large percentage of elongated (mesenchymal-like) cells, significantly
increased the amoeboid population compared with the nonsilencing
(LV-NS) control (Figures 1D and W2C ). Finally, PEDF dramati-
cally increased the number of focal adhesions, indicative of a mesenchy-
mal, adherent phenotype, as was demonstrated by immunofluorescence
for vinculin (Figure 1E). Therefore, in melanoma, PEDF promoted a
mesenchymal-like morphology and its loss enabled the transition to
an amoeboid phenotype.
PEDF Inhibits Extravasation to the Lung
Invasion is a key requirement for tumor cell extravasation from the
blood vessels and colonization at remote sites. Because rapid extra-
vasation is associated with the amoeboid morphology [5,29], we tested
whether PEDF can block extravasation from the lung vasculature. In a
short-term lung colonization assay, we injected the mouse tail vein with
A375 melanoma overexpressing PEDF (LV-PEDF) or infected with
control lentivirus (LV-C). Two hours after injection, equal numbers
of PEDF-positive (LV-PEDF) and PEDF-null (LV-C) cells could be
seen at the lung surface in a pattern following that of the lung vascu-
lature (Figure 1F ). Later, 22 to 24 hours after injection, only GFP-
positive cells that escaped from circulation remained visible at the lung
surface; extravasation of PEDF-positive cells was significantly lower
than in control, suggesting that PEDF opposes lung extravasation
and rapid invasion—a process associated with amoeboid morphology
[29] (Figure 1G).
Figure 1. PEDF promotes mesenchymal morphology and blocks lung extravasation. (A and B) A375 cells expressing inducible PEDF
(iPEDF) were treated with shield1 (250 nM) to induce PEDF expression, and images were obtained at indicated time points (A). The
lysates were collected 30 minutes after induction, and MLC phosphorylation was measured by Western blot (B). (C) A375 cells consti-
tutively expressing PEDF (LV-PEDF) or vector control (LV-C) were seeded on a thick collagen bed where LV-PEDF showed a significantly
higher proportion of mesenchymal cells. The data are expressed as percent elongated or rounded cells per field (10 random fields and
>500 cells were examined per experiment). **P < .01. Error bars indicate standard deviation. (D) SBcl2 melanoma, expressing high
endogenous PEDF infected with nonsilencing control, LV-NS, or LV-shPEDF were grown on collagen; PEDF knockdown significantly
increased the rounded (amoeboid) cell population. **P < .01. (E) In A375 cells transduced with the lentiviral vector expressing PEDF
(LV-PEDF) or control virus (LV-C), focal contacts were visualized by vinculin immunofluorescence. (F and G) Extravasation assay was
performed with A375 (LV-C) or A375 (LV-PEDF) cells injected into the tail vein of nude mice. Lung surfaces were examined for GFP-
expressing tumor cells 2 (F) and 20 hours (G) after injection. GFP-positive colonies were imaged using Nikon AZ-100 and analyzed using
Metamorph software; SEM values are shown. *P < .05.
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PEDF Suppresses Amoeboid Phenotype by Increasing
Rac1 Activation
Cytoskeletal rearrangements critical for migration and invasion are
regulated by the Rho GTPases, RhoA, Rac1, and Cdc42 [30]. Rho
and Rac both support migration but exert opposing effects on cell
shape; RhoA promotes an amoeboid morphology and rapid invasion,
whereas Rac1 supports an adherent, elongated phenotype and slow
invasion [31–36]. We found that PEDF overexpression reduced RhoA
activity in A375 melanoma cells (Figure 2, A and B). In contrast, PEDF
overexpression or treatment with recombinant PEDF (rPEDF) in-
creased active Rac1-GTP (Figure 2, B and C ). In agreement, Rac1
inhibitor, NSC23766, abrogated the increase in mesenchymal-like
population caused by PEDF overexpression in A375 cells (Figure 2D).
Further, blocking the Rho pathway with the ROCK inhibitor, Y27632,
mimicked PEDF’s ability to stimulate an elongated morphology
(Figure 2D). Thus, the shift of the Rho/Rac balance in favor of Rac1
was critical for the decrease of the amoeboid population. In vivo, Rac1
silencing using lentiviral shRNA (Figure W2D; LV-shRac1) reversed
the ability of PEDF to suppress extravasation (Figure 2, E and F). Fi-
nally, PEDF overexpression in A375 and C8161 (highly aggressive and
PEDF-negative melanoma) cells dramatically altered their F-actin pro-
file by reducing cortical actin, typical of the amoeboid morphology, and
stimulating the formation of stress fibers, a characteristic of protease-
dependent, mesenchymal-like invasion (Figure 2G ). Taken together,
our data show that PEDF shifts the balance between RhoA and Rac1
in favor of Rac1 and promotes mesenchymal-like state associated with a
significant decrease in extravasation in vivo.
PEDF Requires DOCK3 and WAVE2 to Promote an
Elongated Morphology
The guanine nucleotide exchange factors (GEFs), DOCK3 and
DOCK10, and the GTPase-activating protein (GAP), ARHGAP22,
modify Rho GTPase functions that determine elongated or rounded
phenotypes [5,28]. We measured their expression in A375 control
and PEDF-expressing cells (LV-PEDF) by qRT-PCR. PEDF did not
have a clear effect on DOCK10, the GEF that regulates Cdc42 [28];
in agreement, PEDF had no effect on Cdc42 activity (Figure W5).
In contrast, PEDF increased the expression of Rac1-specific GEF,
DOCK3 (Figure 3B), and suppressed a Rho-dependent inhibitor of
Rac1, ARHGAP22 (Figure 3A). Treatment of parental A375 cells with
rPEDF also reduced ARHGAP22 (Figure W6) and increased DOCK3
(Figure 3B). We used lentiviral vectors encoding shRNA for DOCK3,
ARHGAP22, and Rac1 downstream target, WAVE2, which caused at
least 70% knockdown of their respective targets as was measured by
qRT-PCR (Figure W1). Furthermore, Rac1 pull-down assay showed
that DOCK3 silencing decreased active Rac1, whereas ARHGAP22
knockdown modestly increased Rac1 activation (Figure 3C ). To
Figure 2. PEDF regulates lung extravasation by modulating the balance of active RhoA and Rac1. (A and B) Rho and Rac pull-down
assays were performed on A375melanoma cells constitutively expressing PEDF (LV-PEDF) or vector control (LV-C): “C” indicates positive
control provided with the kit. (C) Time course of Rac1 activation using 10 nM recombinant human PEDF (rPEDF). (D) The effects of RhoA
and Rac1 on cell morphology: A375 LV-PEDF and A375 LV-C cells were grown on a thick collagen layer. Rho inhibitor, Y27632 (Y27), and
Rac1 inhibitor, NSC23766 (N237) were added where indicated and incubated overnight. (E and F) Lung extravasation of A375 melanoma
cells transduced with the indicated combinations of LV-C and LV-PEDF with LV-NS (nonsilencing control) or LVshRac1. Pictures shown
are representative images taken 20 hours after injection. *P< .05. (G) F-actin profile of A375 and C8161 (HA) melanoma cells transduced
with LV-C or LV-PEDF and stained with fluorescence-labeled phalloidin.
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determine whether DOCK3, WAVE2, or ARHGAP22 contributes to
the PEDF-dependent AMT, we assessed cell morphology in a three-
dimensional collagen matrix. In the absence of DOCK3 or Rac1 down-
stream effector, WAVE2, PEDF-expressing A375 cells (LV-PEDF)
retained a rounded, amoeboid morphology, and ARHGAP22 silencing
was sufficient to promote an elongated morphology in control (LV-C)
A375 cells (Figure 3D). Together, these results suggest that PEDF ac-
tivates DOCK3 GEF and inactivates ARHGAP22 to cause the shift of
the Rho/Rac balance in favor of Rac1 and subsequent accumulation of
adherent, mesenchymal-like cells. PEDF’s requirement for DOCK3 to
suppress A375 extravasation in vivo (Figure 3, E and F) further sup-
ported Rac1 involvement.
PEDF Blocks MT1-MMP Cell Surface Localization
by Blocking RhoA and Activating Rac1
MT1-MMP activity is critical for migration and invasion of adher-
ent cells [4]. Given that PEDF promotes cell spreading and suppresses
migration, invasion, and metastasis [37], we investigated MT1-MMP
function and distribution in melanoma cells overexpressing PEDF.
We first tested and registered a moderate inhibition of MMP-2 activ-
ity by gelatin zymography in A375 LV-PEDF cells compared with
LV-C but were unable to detect a difference in MMP-2 protein levels
by Western blot (Figures 4A and W7, A and B). However, PEDF
knockdown (LV-shPEDF) in SBcl2 cells, which express high levels
of PEDF and are poorly aggressive, increased MMP-2 activity by gel-
atin zymography (Figures 4, A and B, and W7B).
Importantly, we found that forced PEDF expression or exogenous
PEDF (Figure W7C ) blocked MT1-MMP localization to the cell
surface and confined it to the perinuclear region, a pattern not ob-
served in LV-C controls (Figure 4C ). Treatment of A375 LV-PEDF
cells with Rac1 inhibitor, NSC23766, reversed PEDF’s effect by caus-
ing MT1-MMP redistribution to the cell periphery. In contrast, Rho/
ROCK inhibitor, Y27632, caused MT1-MMP perinuclear localization
in A375 LV-C cells (Figure 4D). These results suggest that, similar to
AMT, PEDF regulates MT1-MMP distribution through RhoA/Rac1
balance. To identify other molecular mediators, we silenced ARH-
GAP22 or DOCK3. ARHGAP22 knockdown phenocopied the
MT1-MMP perinuclear localization caused by PEDF (Figure 4E). In
contrast, LV-shDOCK3 restored MT1-MMP distribution in A375
LV-PEDF cells (Figure 4F ). MT1-MMP overexpression in A375
LV-PEDF cells also restored their ability to extravasate in vivo in the
short-term lung colonization assay (Figures 4, G and H , and W8).
PEDF Drives AMT through the 34-mer Functional Epitope
and Cell Surface Receptor, PEDF-R
Studies by our group and others ascribed PEDF’s antiangiogenic
and neurotrophic activities to the distinct N-terminal peptides, the
34-mer and 44-mer, respectively [27,38,39]. To determine which
fragment causes AMT, we generated lentiviral vectors encoding the
34-mer (LV-34mer) and the 44-mer (LV-44mer) peptides (Figure W9).
The ability to induce AMT in the three-dimensional matrix was main-
tained by the 34-mer but not by the 44-mer (Figure 5, A and B). In
concert, the 34-mer, but not the 44-mer, suppressed MT1-MMP dis-
tribution and increased the number of focal contacts as was measured
by vinculin immunofluorescence (Figure 5, C and D). Therefore,
PEDF’s antimetastatic functions, including the ability to suppress
Figure 3. PEDF attenuates ARHGAP22 expression and requires DOCK3 and WAVE2 to stimulate mesenchymal morphology. (A) Suppres-
sion of ARHGAP22 expression by PEDF (qRT-PCR). (B) DOCK3 protein expression in A375 cells infected with LV-C or LV-PEDF or treated
overnight with 10 nM recombinant PEDF (rPEDF). (C) Rac1 pull-down assay in A375 cells after DOCK3 (LV-shDOCK3) or ARHGAP22
(LV-ARHGAP22) knockdown and quantification with ImageJ software. (D) Amoeboid/mesenchymal morphology of A375 LV-C or A375
LV-PEDF transduced with LV-shARHGAP22, LV-shDOCK3, LV-shWAVE2, or control LV-NS and grown on collagen. Data are shown as
percent elongated cells per field. **P < .01. (E and F) Lung extravasation of A375 melanoma cells transduced with the indicated combina-
tions of LV-C and LV-PEDF with LV-NS and LV-shDOCK3. Quantitative analysis of the experiment: highly significant increase in lung col-
onies formed when PEDF is overexpressed in the absence of shDOCK3 when compared with LV-PEDF. *P < .05. **P < .01.
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Figure 4. PEDF restricts MT1-MMP surface localization by suppressing ARHGAP22. (A and B) MMP-2 activity measured by gelatin zy-
mography in A375 LV-C and A375 LV-PEDF (A) and in SBcl2 LV-NS and SBcl2 LV-shPEDF cells (B). LV-C and LV-NS were used as con-
trols. (C) MT1-MMP localization in A375 LV-PEDF and control (LV-C) cells. (D) Role of Rac1 in PEDF’s effect on MT1-MMP: the
distribution from the perinuclear area to the cell periphery is reversed by treatment with Rac1 inhibitor, NSC23766. Note similar effect
on A375 LV-C. Rho/ROCK inhibitor, Y27632, mimics perinuclear localization of MT1-MMP caused by PEDF. (E and F) MT1-MMP distri-
bution in A375 LV-C cells after ARHGAP22 silencing with LV-shARHGAP22 (E) and in A375 LV-PEDF after DOCK3 silencing with LV-
shDOCK (F). (G and H) Decreased A375 extravasation caused by LV-PEDF was overcome by overexpression of MT1-MMP. **P <
.01. Error bars, SEM.
Figure 5. PEDF regulates AMT through the 34-mer epitope and PEDF-R cell surface receptor. (A and B) We generated A375 cells with
lentiviral overexpression of PEDF, the 34-mer, and the 44-mer (LV-PEDF, LV-34mer, LV-44mer) and analyzed their morphology on col-
lagen gels. A representative of three independent experiments is shown. *P < .05. (C) Focal adhesions were visualized by vinculin
immunostaining. (D) MT1-MMP staining of A375 LV-34mer or A375 LV-44mer. (E) A375 LV-C and A375 LV-PEDF were infected with
lentiviral vectors encoding shRNA targeting the two known PEDF receptors, PEDF-R (LV-shPEDF-R) or LR (LV-shLR), and morphology
was analyzed by collagen assay. Data are presented as the percent elongated cells per field. *P < .05. Error bars, SD per field.
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amoeboid invasion and blockMT1-MMP, reside in the 34-mer, PEDF
fragment, previously identified as antiangiogenic.
Currently, two PEDF binding partners and putative surface recep-
tors are known, PNPLA2 (PEDF-R) and nonintegrin 37/67-kDa lami-
nin receptor (LR) [40,41]. We silenced each candidate receptor in
A375 melanoma using lentiviral vectors encoding the respective shRNA
(Figure W1) and counted cells with amoeboid and mesenchymal-
like morphology when grown on a thick layer of collagen. Despite
the fact that LR is expressed at higher levels than PEDF-R in A375
melanoma (Figure W10), we found that PEDF-R knockdown elimi-
nated the increase in the elongated population due to PEDF, whereas
LR silencing had no effect (Figure 5E). Concurrently, we found that
PEDF-R is required for the 34-mer to promote elongated morphology
(Figure W11).
Discussion
Cell invasion is a critical component of metastasis and can occur by
mesenchymal or amoeboid invasion strategies. Spindle-shaped mesen-
chymal cells with a rigid cytoskeleton rely on proteolysis to generate
de novo tunnels in surrounding matrix, whereas rounded amoeboid
cells possess highly contractile cortical actin that allow rapid shape
deformability and penetration through existing gaps in a protease-
independent manner [17,42,43]. Plasticity, the ability to rapidly
switch between mesenchymal and amoeboid invasion, provides highly
aggressive tumors with extreme adaptability to diverse tissue micro-
environments. Thus far, it was unclear if the shape and proteolytic
activity of the tumor cells are controlled independently or through
related signaling pathways. Our study, for the first time, identifies
an extracellular factor and its cognate receptor, PEDF-R, which pro-
motes the mesenchymal-like phenotype and restricts surface distribu-
tion and function of MT1-MMP, a key protease for the invasion of
adherent tumor cells.
PEDF is ubiquitously expressed and has potent antiangiogenic ac-
tivity; it inhibits migration and invasion of the endothelial and tumor
cells and halts melanoma metastasis [14,15]. We previously demon-
strated that PEDF is expressed at high levels by normal melanocytes
and is lost during the transition to a highly invasive, aggressive mela-
noma [14]. Here, we identify key cellular functions and signaling
pathways regulated by PEDF to suppress tumor metastasis (Figure 6).
We found that PEDF promoted an elongated, adherent phenotype
in melanoma, as was evidenced by the decreased MLC phosphoryla-
tion, increased number of elongated cells, focal contacts, and stress
fiber formation. Given that PEDF blocks vasculogenic mimicry in
melanoma [14] and promotes neuronal differentiation [44,45], it is
not unexpected that it also regulates cellular morphology in melano-
ma, a disease of melanocytes—the cells of neural crest origin. We
demonstrate that PEDF promotes AMT through a previously identi-
fied mechanism, pushing the balance between active RhoA and Rac1
in favor of Rac1, and that Rac1-GEF, DOCK3, and the Rac1 inhib-
itor, ARHGAP22, are critical regulators of this balance. We discov-
ered that PEDF blocked proteolysis, which is required for the
mesenchymal-like cells to invade, by causing MT1-MMP redistri-
bution to the perinuclear region. Surprisingly, the redistribution of
MT1-MMP was also mediated through the alteration of the RhoA/
Rac1 balance, where the Rho inhibitor mimicked perinuclear accu-
mulation of MT1-MMP by PEDF and the Rac1 inhibitor restored
MT1-MMP membrane localization when PEDF was overexpressed.
The evidence in favor of Rac1 precluding MT1-MMP trafficking to
the cell surface was further solidified when ARHGAP22 silencing
increased perinuclear MT1-MMP and DOCK3 knockdown restored
MT1-MMP distribution to the cell membrane. Together, our find-
ings clearly demonstrate that the balance between active Rac1 and
RhoA regulate MT1-MMP subcellular localization and therefore activ-
ity. Our study pinpoints a relationship between the signaling compo-
nents in control of cellular morphology andMT1-MMP distribution in
the tumor context.
Several studies highlight the significance of MT1-MMP signaling
and function in organ development and in tumor progression and dem-
onstrate its critical role in mesenchymal movement [17]. In mammary
epithelial tubule model, cells sort according to MT1-MMP expression
and Rho kinase signaling [46]. Moreover, Cdc42 and MT1-MMP are
essential for the single-cell invasion in three-dimensional cultures; it has
been proposed that coordinated Cdc42 and MT1-MMP activity allow
the formation of single-cell invasion tunnels through which fibro-
sarcoma cells subsequently invade [43]. Bone marrow myeloid progen-
itor cells require MT1-MMP to maintain typical cell morphology,
lamellipodia formation, and motility [47]. By overexpressing MT1-
MMP, we were able to override PEDF’s antimetastatic effect and re-
store extravasation; thus, MT1-MMP blockade and Rac1 activation
are critical drivers of PEDF’s antimetastatic function.
While significant progress has been made in defining intracellular
events that control tumor cell morphology, the extracellular cues
that drive this transition remained unknown. Matrix stiffness is
Figure 6. Summary of the signaling pathways altered by PEDF to
suppress amoeboid morphology and proteolysis, extravasation,
and metastasis. PEDF, via the 34-mer epitope, activates PEDF-R,
which blocks RhoA activation and represses ARHGAP22, an inhib-
itor of Rac1 activity. At the same time, PEDF stimulates DOCK3
expression, which drives Rac1 activity and, consequently, WAVE2
signaling. The net result is increased active Rac1 and a consequent
shift in the balance of active Rac1/RhoA in favor of Rac1, which
drives AMT and the accumulation of the mesenchymal-like cells.
At the same time, PEDF, through the 34-mer epitope, restricts
MT1-MMP (denoted as scissors) surface localization and conse-
quent signaling. Therefore, endogenous PEDF blocks melanoma
lung extravasation by “locking” melanoma cells in a mesenchymal
state and simultaneously inhibiting MT1-MMP, a critical player for
mesenchymal-mediated extravasation.
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one important determinant of the modes in which macrophage-
derived blood monocytes move [48]. PEDF is a secreted, ubiqui-
tously expressed protein, which can be incorporated into the
ECM, and belongs to a class of matricellular proteins, which also in-
cludes thrombospondin [49]. We identified PEDF as a paracrine fac-
tor that controls the reversible transition between mesenchymal-like
and amoeboid morphology and blocks MT1-MMP function. Fur-
thermore, we identified an active PEDF peptide, the 34-mer, and cell
surface receptor, PEDF-R, that transmits this signal. In support of
the fact that PEDF-R drives Rac1, we have preliminary data demon-
strating that PEDF promotes melanosome dispersion and melano-
genesis, a pathway stimulated by a secreted phospholipase A2 [50],
in melanocytes and B16F10 melanoma by increasing cAMP, a robust
inducer of Rac1.
In conclusion, we identified a previously unknown function of
PEDF, where it suppresses melanoma metastasis by locking the cells
in a mesenchymal-like state while abrogating MT1-MMP and proteol-
ysis. Further, we outline a molecular mechanism through which PEDF
elicits its antimetastatic effects. Given that we previously identified an
18-amino acid active peptide that maintains the 34-mer functional ac-
tivity [51], this study could yield a new drug for prevention of metastasis.
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Supplementary Methods
shRNAmir Constructs
All constructs were purchased from Open Biosystems (underlined
clones refer to the most efficient vector to knockdown each respec-
tive transcript).
PEDF:
VL2HS_221662 shRNAmir
PEDF-R:
V2LHS_215390 shRNAmir
V2LHS_216192 shRNAmir
Laminin receptor:
V2LHS_271522 shRNAmir
V2LHS_133908 shRNAmir
DOCK3:
V2LHS_64763 shRNAmir
V2LHS_64761 shRNAmir
WAVE2:
V2LHS_95116 shRNAmir
V2LHS_269093 shRNAmir
ARHGAP22:
V3LHS_393447 shRNAmir
V3LHS_393444 shRNAmir
Primer Sequences for Real-time PCR
DOCK3:
Forward: 5′-ACA GAG AAG TAC GGC CTG TTG GTT-3′
Reverse: 5′-ACG TGT CCA TCA CAG GTC GAA AGT-3′
ARHGAP22:
Forward 5′-AGA AGG GAG TGC TGA CCT GAG AAA-3′
Reverse: 5′-ACT CCT CCA TTT CCC TCT GCA ACA-3′
DOCK10:
Forward: 5′-AGC AGT TCT GCA CCA CTC TCA GAA-3′
Reverse: 5′-AAC TGA CGT TTC CAG AGC CTC CTT-3′
WAVE2:
Forward: 5′-CCA AAC CTT TCC CTG AAG CAA CCA-3′
Reverse: 5′-ACA GGC ACT TGA AGG AAA GAG GGA-3′
PEDF-R
Forward: 5′-GCA GTT TCC TGC TGA AGG TC-3′
Reverse: 5′-GCT CGT CCT TGG AGT TGA-3′
LR
Forward: 5′-AGA AGG CAG TGA CCA AGG AGG AAT-3′
Reverse: 5′-ATT GCT GAA TAG GCA CAG AGG GCA-3′
Cloning Strategy for PEDF Fragments
N-terminal fragment (N-Ter). Target sequence was amplified
from a previously described clone, pcDNA4/TO/myc-His expressing
the PEDF N-Terminus [1] using the following primer sequences:
DNA: pcDNA4/TO/myc-His-N-Ter
Forward: 5′-CGGTCTAGAAGGATGCAGGCCCTGGTG-3′
Reverse: 5′-CCCTCGAGACTCAATGGTGATGGTGATGGTG-
GGTACCATGGATG-3′
34-Mer. The 34-mer sequence was amplified from pcDNA4/TO/
myc-His-34-mer [1] using the following primer sequences:
DNA: pcDNA4/TO/myc-His-34-mer [1]
Forward: 5-GGGCACAGCAGCTGCGATCCTTTCTTCAAAG-3
Reverse: 5′-CCCTCGAGACTCAATGGTGATGGTGATGGTG-
GTTGGTCGTGGG-3′
44-Mer. The 44-mer PEDF epitope was amplified from pcDNA4/
TO/myc-His-44-mer [1] using:
DNA: pcDNA4/TO/myc-His-44-mer [1]
Forward: 5′-GGGCACAGCAGCTGCGTGCTCCTGTCTCCTC-3′
Reverse: 5′-CCCTCGAGACTCAATGGTGATGGTGATGGTG-
GGTACCATGGATG-3
The resultant PCR product(s) were then inserted into the lentiviral
vector, prrl.CMV.EGFP.wpre.SIN [2] obtained from L. Naldini (San
Raffaele – Telethon Institute for Gene Therapy, Milan, Italy) and pre-
viously used by our group [3].
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Figure W1. Silencing of gene targets. Quantitative RT-PCR of total mRNA samples isolated from A375 cells transduced with lentiviral
vectors encoding shRNA targeting DOCK3, WAVE2, ARHGAP22, LR, PEDF-R, or nonsilencing control (NS).
Figure W2. Manipulation of PEDF and Rac1 expression. (A) Western blot measuring PEDF expression A375 lysate transduced with
inducible PEDF (iPEDF) and treated with 250 nM shield1 (inducer) for the indicated time points. (B) Western blot probing for PEDF in
cell lysate and ELISA data (right) quantifying PEDF expression in the conditioned medium of A375 melanoma transduced with bicistronic
lentivirus expressing LV-C (GFP only) or LV-PEDF (GFP and PEDF). (C) Western blot on conditioned medium of SBcl2 melanoma trans-
duced with nonsilencer control (LV-NS) or shRNA targeting PEDF (LV-shPEDF). (D) Western blot for Rac1 in A375 LV-C and LV-PEDF
lysate transduced with lentivirus encoding shRac1 (LV-shRac1) or nontargeting vector (LV-NS).
Figure W3. PEDF controls cell shape. Images of A375 melanoma
(top) and melanocytes (bottom) transduced with LV-C or LV-PEDF
(A375) and LV-NS or LV-shPEDF (melanocytes).
Figure W4. Exogenous PEDF promotes an elongated morphology. Amoeboid/mesenchymal morphology assay measuring the ability of
10 nM recombinant PEDF (rPEDF) to promote an elongated morphology in A375 melanoma. (A) Representative image of cells grown on
a thick layer of collagen and (B) quantification. *P < .05. Error bars, SD.
Figure W5. PEDF expression does not effect cdc42 activity. Pull-
down assay measuring cdc42 activity in A375 iPEDF 30 minutes
after PEDF induction with shield1.
Figure W7. Exogenous PEDF redistributes MT1-MMP and moderately suppresses MMP-2. (A) Western blot (left) on the conditioned
medium of A375 melanoma treated with 10 nM PEDF and a quantification (right) of the inactive MMP-2 band. No difference was seen in
totalMMP-2. (B) Gelatin zymography of A375 and SBcl2melanomawith the indicated treatments. (C) Immunofluorescence forMT1-MMP in
A375 treated with exogenous PEDF. A concentration of 10 nM PEDF was used in all experiments.
Figure W8.MT1-MMP overexpression. Measurement of MT1-MMP overexpression in A375 by qRT-PCR (top) and conventional RT-PCR
(bottom) after transfection with plasmid (pcDNA3.1(+)) encoding MT1-MMP.
Figure W6. PEDF represses ARHGAP22. QRT-PCR of cDNA from
A375 treated overnight with 10 nM recombinant PEDF compared
with control vehicle.
Figure W11. PEDF-R is required for 34-mer–induced elongated morphology. Amoeboid/mesenchymal morphology assay in A375 mel-
anoma overexpressing the PEDF, 34-mer, and infected with lentivirus encoding shRNA targeting LR, PEDF-R, or nonsilencing control.
Representative image (A) and quantification (B) are shown. **P < .01.
Figure W9. Relative expression of 34-mer and 44-mer. Quantita-
tive RT-PCR measuring the relative expression of forced 34-mer
and 44-mer by lentivirus. The graphs indicate the fold increase com-
pared the LV-C.
Figure W10. Relative expression of PEDF-R and LR. Quantitative
RT-PCR of cDNA extracted from A375 LV-C melanoma measuring
the relative expression of PEDF-R and LR.
